Insomnia drug approved in Europe
Studies have shown that this drug improves sleep and daytime performance in people with insomnia, without causing a sedative effect the next day, as1
Studies have shown that this drug improves sleep and daytime performance in people with insomnia, without causing a sedative effect the next day, as1
Researchers from the Hospital Clínic-IDIBAPS are leading a study to obtain information on 10,000 healthy people who do not have Parkinson\'s disease,1
Early diagnosis, a protein-free diet and treatment with a cofactor called BH4 make it possible for patients with this disease to develop normally. A1
On 24 February, the Russian President Vladimir Putin ordered an attack on the Donbas region of Ukraine. It was the start of a war with incalculable c1
The Joan Rodés-Josep Baselga Advanced Research Contracts in Oncology and Neurodegenerative Diseases, awarded by the BBVA Foundation and Hospital Clín1
A Harvard University study of 10 million people finds that 97% of people with multiple sclerosis have been infected by the Epstein-Barr virus. This d1
The study, led by researchers from Hospital Clínic-IDIBAPS, will be a paradigm shift in the treatment of the disease worldwide
Dr. Josep Baselga, an internationally renowned medical oncologist, died of this degenerative disease on 21 March 2021. The meeting was attended by Dr1
From September 2021, Cannabidiol (CBD) will be marketed in Spain as the first medication used to treat refractory epilepsy, which does not respond we1
Cardiology, cardiac surgery, orthopaedic surgery and traumatology, gastroenterology, endocrinology and nutrition, neurology and medical oncology are1